

Lukas Flatz is Head of the Division of Dermato-oncology at the University of Tübingen Skin Cancer Center. Lukas Flatz studied medicine in Bern, Switzerland. In his doctoral thesis with Dr. Cottagnoud, he investigated mechanisms of antibiotic resistance. During his postgraduate training with Dr. Hengartner and Nobel Laureate Dr. Zinkernagel at the University/ETH of Zurich (Zurich, Switzerland) he acquired hands-on knowledge in basic immunology and infection biology. He then joined Dr. Nabel's research group at the National Institutes of Health in Bethesda, MD (USA) for a postdoctoral fellowship. This was followed by a residency in dermatology at the University Hospital of Lausanne, Switzerland. He is board-certified in dermatology and leads an independent research group. His team aims to decipher the mechanisms and toxicity of checkpoint inhibitors (www.flatzlab.com). From 2016 to 2020 he was a Swiss National Science Foundation professor and a full member of the medical faculty at the University of Zurich. In 2019 he completed a diploma of advanced studies in pharmaceutical medicine at the European Center of Pharmaceutical Medicine (ECPM) at the University of Basel, Switzerland. Since 2021 he is a professor of dermatology at the University of Tübingen.